Dal, Mehmet SinanUlu, Bahar UncuUzay, AntAkay, Olga MeltemBeşışık, SevgiYenerel, Mustafa NuriÇelik, SerhatKaynar, LeylagülYücel, Orhan KemalDeveci, BurakSönmez, MehmetMehtap, ÖzgürBeköz, Hüseyin SaffetSunu, CenkSalim, OzanUlaş, TurgayKartı, SamiAltuntaş, FevziFerhanoğlu, BurhanTuğlular, Tülin Fırat2023-02-232023-02-232023Dal, M. S., Ulu, B. U., Uzay, A., Akay, O. M., Beşışık, S., Yenerel, M. N. ... Tuğlular, T. F. (2023). Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey. Annals of Hematology, 102(1), 133-140. https://doi.org/10.1007/s00277-022-05052-x0939-55551432-0584https://doi.org/10.1007/s00277-022-05052-xhttps://hdl.handle.net/20.500.12511/10517Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m2 on day 1, and bendamustine 90 mg/m2 on days 1–2 of each cycle. Median age at Pola-BR initiation was 55 (19–84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3–4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.eninfo:eu-repo/semantics/openAccessBendamustineDiffuse Large B-cell LymphomaPolatuzumab VedotinRefractoryRelapsedRituximabArticle102113314010.1007/s00277-022-05052-xQ20008854014000022-s2.0-8514226528236401621Q1